Mandate

Vinge has advised Egetis Therapeutics in connection with a combined financing comprising an equity private placement and debt financing

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a combined financing comprising a SEK 172 million equity private placement and a SEK 290 million debt financing.

Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson, Lorin Arabi and Isabell Bitar (Capital Markets and Public M&A) and of Albert Wållgren, Arvid Weimers and Ida Redander (Banking and finance).

Related

Vinge advises Symrise on its public offer for Probi

Symrise AG has announced a public cash offer to the shareholders of Probi AB (publ) (“Probi”). The offer values Probi at approximately SEK 3,988 million. The shares in Probi are traded on Nasdaq Stockholm, Mid Cap.
November 20, 2024

Vinge advises Oxx in conjunction with an investment in Kodiak Hub

Kodiak Hub, a Swedish software as a service (SaaS) company, which offers its customers an AI-based software platform, has performed a capital procurement of EUR 6 million. The venture capital fund Oxx, which invests in SaaS companies, is the largest investor.
November 20, 2024

Vinge advises HAKI Safety AB (publ) in connection with the acquisition of Semmco Group Limited

Semmco Group is a UK market-leading manufacturer and supplier of maintenance platforms and stairs for aircraft and trains.
November 19, 2024